ReviewFungal biology reviews2021
The rise in cases of mucormycosis, candidiasis and aspergillosis amidst COVID19.
Review in Fungal biology reviews, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Surface-Engineered Filters for Wettability-Driven Collection of Airborne Fungal Spores.Global challenges (Hoboken, NJ) · 2026Article
- Review
- Impact of COVID-19 on sputum isolates and hospital outcomes among patients with pneumonia in Sheffield, United Kingdom: a retrospective cohort study.Frontiers in public health · 2026Article
- Review
- Overcoming antifungal resistance inFrontiers in cellular and infection microbiology · 2025Review
- Invasive Fungal Infections in Immunocompromised Conditions: Emphasis on COVID-19.Current microbiology · 2024Review
- Nanotechnology-based fungal detection and treatment: current status and future perspective.Naunyn-Schmiedeberg's archives of pharmacology · 2024Review
- Transcription Factors Tec1 and Tec2 Play Key Roles in the Hyphal Growth and Virulence of Mucor lusitanicus Through Increased Mitochondrial Oxidative Metabolism.Journal of microbiology (Seoul, Korea) · 2023Article
- Radiological features of COVID-19-associated mucormycosis: A report of 36 cases along with a literature review.Clinical case reports · 2023Article
- Advances in understanding infections caused by the basal fungus Mucor.PLoS pathogens · 2023Article
- Lower Concentrations of Amphotericin B Combined withAntibiotics (Basel, Switzerland) · 2023Article
- Article
- Epidemiology and outcomes of culture-positive bloodstream pathogens prior to and during the SARS-CoV-2 pandemic: a multicenter evaluation.BMC infectious diseases · 2022Article
- Mortality analysis of COVID-19 cases during the second wave and its comparison with the first wave: A hospital-based study.Journal of family medicine and primary care · 2022Article
- Development of a Monoclonal Antibody and a Serodiagnostic Lateral-Flow Device Specific toJournal of fungi (Basel, Switzerland) · 2022Article
- An ubiquitous entity of post-COVID rhinomaxillary mucormycosis.Journal of family medicine and primary care · 2022Article
- Developing Novel Biointerfaces: Using Chlorhexidine Surface Attachment as a Method for Creating Anti-Fungal Surfaces.Global challenges (Hoboken, NJ) · 2022Article
- In Vitro Activity of Amphotericin B in Combination with Colistin against Fungi Responsible for Invasive Infections.Journal of fungi (Basel, Switzerland) · 2022Article
- Fungal Infections Other Than Invasive Aspergillosis in COVID-19 Patients.Journal of fungi (Basel, Switzerland) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Coronavirus outbreak globally has changed the medical system and also led to a shortage of medical facilities in both developing and underdeveloped countries. The COVID19 disease, being novel in nature along with high infectivity and frequent mutational rate, has been termed to be fatal across the globe. The advent of infection by SARS-CoV-2 has brought a myriad of secondary complications and comorbidities resulting in additional challenges to the health care system induced by novel therapeutic procedures. The emerging variant with respect to the Indian subcontinent and the associated genetic mutations have worsened the situation at hand. Proper clinical management along with epidemiological studies and clinical presentations in scientific studies and trials is necessary in order to combat the simultaneous waves of emerging strains. This article summarizes three of the major fungal outbreaks in India namely mucormycosis, candidiasis and aspergillosis, and elaborates their subtypes, pathogenesis, symptoms and treatment and detection techniques. A detail of future therapeutics under consideration are also elaborated along with a general hypothesis on how COVID19 is related to immunological advances leading to major widespread fungal infection in the country. The factors that contribute in promoting virus proliferation and invasive fungal infections include cell-mediated immunity, associated immunocompromised conditions and treatment protocols that slows down immune mechanisms. To better comprehend a fungal or bacterial outbreak, it is very important to conduct audits mediated through multicenter national and state research teams for recognizing patterns and studying current cases of fungal infection in both healthy and comorbid groups of COVID19 patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.